Images List Premium Download Classic

Dyslipidemia

Dyslipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
May 10, 2018 - N°20180127476

Z4, z7, z9, z11, z22, z23, z26, z30, z34, z35, p, m, n, q, and bridge are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof.
Methods and formulations for modulating lyn kinase activity and treating related disorders
Melior Pharmaceuticals I, Inc.
May 10, 2018 - N°20180125845

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, ...
Growth differentiation factor 15 (gdf-15) constructs
Amgen Inc.
March 22, 2018 - N°20180079790

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 22, 2018 - N°20180050083

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
Shenzhen Hjghtide-biopharmageutical, Ltd.
February 22, 2018 - N°20180050048

The invention provides novel conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or r-(+)-α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or cinnamic acid, or cholic acid, or oleanolic acid, or salicylic acid, or betulinic acid, or chlorogenic acid, or ...
Methods of treating mixed dyslipidemia
Amarin Pharmaceuticals Ireland Limited
February 15, 2018 - N°20180042880

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.. .
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of preventing the occurrence of cardiovascular events
Kowa Company, Ltd.
February 01, 2018 - N°20180028506

The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events..
Methods of preventing cardiovascular events in residual risk dyslipidemic populations
Kowa Company, Ltd.
February 01, 2018 - N°20180028505

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled ldl-c concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 ...
Methods and tools for diagnosing insulin resistance and assessing health status using nmr relaxation times ...
University Of North Texas Health Science Center At Fort Worth
January 25, 2018 - N°20180020947

The subject invention pertains to a method that involves at least three steps: (1) acquisition of a nmr data set or spin relaxation curve for plasma, serum or whole blood samples, or for tissues monitored from outside the body, (2) analysis of the nmr data or relaxation curve to extract the t2 and/or t1 relaxation times for water (or surrogates thereof), ...
Method of treating or ameliorating type 1 diabetes using fgf21
Amgen Inc.
January 04, 2018 - N°20180000898

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa ...
Dezima Pharma B.v.
January 04, 2018 - N°20180000818

The present invention relates to a pharmaceutical composition and a therapeutic combination comprising a novel cholesteryl ester transfer protein (cetp) inhibitor and a hmg coa reductase inhibitor, which may be used in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia.. .
Methods for the treatment of polycystic ovary syndrome
Center For Reproducitive Medicine, Shandong Provincial Hospital, Shandong University
December 21, 2017 - N°20170360843

Polycystic ovary syndrome (pcos) is a complex and heterogeneous endocrine syndrome associated with a high risk for the development of insulin resistance, type 2 diabetes (t2d), obesity, dyslipidemia, and cardiovascular disease. There are no known therapies for the 9-18% of women afflicted with pcos.
Hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
December 07, 2017 - N°20170349516

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Omefibrates for treating dyslipidemia and cardiovascular disease
Jiva Pharma, Inc.
November 16, 2017 - N°20170327455

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).. .
Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome
Duke University
November 16, 2017 - N°20170326199

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Novel pentadienoyl piperidine derivative and use thereof
Snu R&db Foundation
November 09, 2017 - N°20170320825

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and ...
Methods for treating patients with familial hypercholesterolemia
November 02, 2017 - N°20170312359

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both hefh and hofh. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angptl3 in combination with a therapeutically effective amount of a ...
Compositions and methods for lipid metabolism disorder
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention ...
Shifa Biomedical Corporation
October 26, 2017 - N°20170305887

Endothelial lipase (el) inhibitors and methods of using such inhibitors for treating conditions implicating el are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of el function that can be used therapeutically to raise hdl cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and ...
Dyslipidemia therapeutic agent
Kowa Company, Ltd.
October 26, 2017 - N°20170304274

This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-ldl cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and or treating dyslipidemia and the like, the drug composition including the following: (r)-2-[3-[[n-(benzoxazol-2-yl)-n-3-(4-methoxyphenoxy)propyl]...
Dyslipidemia therapeutic agent
October 26, 2017 - N°20170304273

This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (r)-2-[3-[[n-(benzoxazol-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (s)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2...
Loading